Suppr超能文献

代偿期肝硬化:自然病程及疾病修饰策略

Compensated liver cirrhosis: Natural course and disease-modifying strategies.

作者信息

Kumar Ramesh, Kumar Sudhir, Prakash Sabbu Surya

机构信息

Department of Gastroenterology, All India Institute of Medical Sciences, Patna 801507, India.

出版信息

World J Methodol. 2023 Sep 20;13(4):179-193. doi: 10.5662/wjm.v13.i4.179.

Abstract

Compensated liver cirrhosis (CLC) is defined as cirrhosis with one or more decompensating events, such as ascites, variceal haemorrhage, or hepatic encephalopathy. Patients with CLC are largely asymptomatic with preserved hepatic function. The transition from CLC to decompensated cirrhosis occurs as a result of a complex interaction between multiple predisposing and precipitating factors. The first decompensation event in CLC patients is considered a significant turning point in the progression of cirrhosis, as it signals a drastic decline in median survival rates from 10-12 years to only 1-2 years. Furthermore, early cirrhosis has the potential to regress as liver fibrosis is a dynamic condition. With the advent of effective non-invasive tools for detecting hepatic fibrosis, more and more patients with CLC are currently being recognised. This offers clinicians a unique opportunity to properly manage such patients in order to achieve cirrhosis regression or, at the very least, prevent its progression. There are numerous emerging approaches for preventing or delaying decompensation in CLC patients. A growing body of evidence indicates that treating the underlying cause can lead to cirrhosis regression, and the use of non-selective beta-blockers can prevent decompensation by lowering portal hypertension. Additionally, addressing various cofactors (such as obesity, diabetes, dyslipidaemia, and alcoholism) and precipitating factors (such as infection, viral hepatitis, and hepatotoxic drugs) that have a detrimental impact on the natural course of cirrhosis may benefit patients with CLC. However, high-quality data must be generated through well-designed and adequately powered randomised clinical trials to validate these disease-modifying techniques for CLC patients. This article discussed the natural history of CLC, risk factors for its progression, and therapeutic approaches that could alter the trajectory of CLC evolution and improve outcomes.

摘要

代偿期肝硬化(CLC)被定义为伴有一个或多个失代偿事件(如腹水、静脉曲张出血或肝性脑病)的肝硬化。CLC患者大多无症状,肝功能保持正常。从CLC转变为失代偿期肝硬化是多种易感因素和促发因素之间复杂相互作用的结果。CLC患者的首次失代偿事件被认为是肝硬化进展中的一个重要转折点,因为它标志着中位生存率从10 - 12年急剧下降至仅1 - 2年。此外,由于肝纤维化是一种动态情况,早期肝硬化有可能逆转。随着有效检测肝纤维化的非侵入性工具的出现,目前越来越多的CLC患者被识别出来。这为临床医生提供了一个独特的机会来妥善管理此类患者,以实现肝硬化逆转,或者至少防止其进展。有许多新兴方法可用于预防或延缓CLC患者的失代偿。越来越多的证据表明,治疗潜在病因可导致肝硬化逆转,使用非选择性β受体阻滞剂可通过降低门静脉高压来预防失代偿。此外,处理对肝硬化自然病程有不利影响的各种辅助因素(如肥胖、糖尿病、血脂异常和酗酒)和促发因素(如感染、病毒性肝炎和肝毒性药物)可能使CLC患者受益。然而,必须通过精心设计且样本量充足的随机临床试验来生成高质量数据,以验证这些针对CLC患者的疾病改善技术。本文讨论了CLC的自然病史、其进展的危险因素以及可改变CLC演变轨迹并改善预后的治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验